{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:17:03Z","timestamp":1790255823616,"version":"4.1.0"},"reference-count":107,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.<\/jats:p>","DOI":"10.3233\/jad-190507","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T11:32:02Z","timestamp":1566905522000},"page":"715-732","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":121,"title":["Developing Effective Alzheimer\u2019s Disease Therapies: Clinical Experience and Future Directions"],"prefix":"10.1177","volume":"71","author":[{"given":"David R.","family":"Elmaleh","sequence":"first","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, Boston, MA, USA"},{"name":"AZTherapies Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Farlow","sequence":"additional","affiliation":[{"name":"Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Conti","sequence":"additional","affiliation":[{"name":"Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Kundakovic","sequence":"additional","affiliation":[{"name":"AZTherapies Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph E.","family":"Tanzi","sequence":"additional","affiliation":[{"name":"Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610203008688"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt269"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.10.003"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1177\/153331750502000206"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.008"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.10.013"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006296"},{"issue":"1","key":"ref008","first-page":"S5","volume":"33","author":"Tanzi RE","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.10.008"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211851"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211103"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03830.x"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2043"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2001-3111"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2005.103754"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.5772\/57398"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(96)13087-1"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1994.1055"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.01344.x"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.2.741"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0486-3"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1038\/nature13800"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.09.018"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24546"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(97)00056-0"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.05.006"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.3390\/biom6010006"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2524"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385883-2.00004-7"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad8373"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.04.014"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0175-4"},{"key":"ref037","first-page":"495243","volume":"2012","author":"Wilcock DM","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.988707"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4132"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007642"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2018.18"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1159\/000096588"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001617"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2009.00121.x"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.07.735"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003904"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.588"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.21.2819"},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311486"},{"key":"ref050","doi-asserted-by":"publisher","DOI":"10.2174\/1567205014666170117141330"},{"key":"ref051","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.2.425"},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(98)00096-7"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.1007\/BF03325217"},{"key":"ref054","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611404470"},{"key":"ref055","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70119-8"},{"key":"ref056","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201709069"},{"key":"ref057","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4587"},{"key":"ref058","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0355-7"},{"key":"ref059","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0089-7"},{"key":"ref060","unstructured":"Axovant, Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer\u2019s Disease, http:\/\/investors.axovant.com\/node\/7286\/pdf, Posted September 26, 2017, Accessed February 13, 2019."},{"key":"ref061","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.20373"},{"key":"ref062","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0368-9"},{"key":"ref063","unstructured":"Sanofi, Clinical Trial Report: SR57746 (xaliproden), https:\/\/www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/common\/docs\/clinical-study-results\/efc2946-summary.pdf, Posted April 4, 2016, Accessed February 13, 2019."},{"key":"ref064","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140291"},{"key":"ref065","doi-asserted-by":"publisher","DOI":"10.2174\/1567205010666131212110148"},{"key":"ref066","unstructured":"Servier, Clinical Study Report: S 38093, http:\/\/clinicaltrials.servier.com\/wp-content\/uploads\/CL2-38093-009_synopsis_report.pdf, Posted March 9, 2012, Accessed February 13, 2019."},{"key":"ref067","unstructured":"BusinessWire, FORUM Pharmaceuticals Inc. Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer\u2019s Disease and Cognitive Impairment in Schizophrenia, https:\/\/www.businesswire.com\/news\/home\/20150914005855\/en\/FORUM-Pharmaceuticals-Updates-Encenicline-Phase-3-Clinical, Posted September 14, 2015, Accessed February 13, 2019."},{"key":"ref068","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181aad585"},{"key":"ref069","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-130872"},{"key":"ref070","unstructured":"Servier, Clinical Study Report: S 47445, https:\/\/clinicaltrials.servier.com\/wp-content\/uploads\/CL2-47445-011-synopsis-report.pdf, Posted June 8, 2018, Accessed February 13, 2019."},{"key":"ref071","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161309"},{"key":"ref072","doi-asserted-by":"publisher","DOI":"10.2174\/156720511795256053"},{"key":"ref073","unstructured":"Janssen, Update on Janssen\u2019s BACE Inhibitor Program, https:\/\/www.janssen.com\/update-janssens-bace-inhibitor-program, Posted May 17, 2018, Accessed February13, 2019."},{"key":"ref074","unstructured":"Lilly Press Release, Update on https:\/\/investor.lilly.com\/node\/39051\/pdf 3 Clinical Trials of Lanabecestat for Alzheimer\u2019s Disease. https:\/\/investor.lilly.com\/node\/39051\/pdf, Posted June 12, 2018, Accessed February13, 2019."},{"key":"ref075","unstructured":"Evaluate, Eli Lilly backs away from Bace but not from novel Alzheimer\u2019s targets, http:\/\/www.evaluate.com\/vantage\/articles\/analysis\/spotlight\/eli-lilly-backs-away-bace-not-novel-alzheimers-targets, Posted November 14, 2018, Accessed March 29, 2019."},{"key":"ref076","unstructured":"Merck Press Release, Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer\u2019s Disease to Stop for Lack of Efficacy, https:\/\/investors.merck.com\/news\/press-release-details\/2017\/Merck-Announces-EPOCH-Study-of-Verubecestat-for-the-Treatment-of-People-with-Mild-to-Moderate-Alzheimers-Disease-to-Stop-for-Lack-of-Efficacy\/, Posted February 14, 2017, Accessed February 13, 2019."},{"key":"ref077","first-page":"1","volume":"3","author":"Coric V","year":"2012","journal-title":"Arch Neurol"},{"key":"ref078","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"ref079","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210951"},{"key":"ref080","unstructured":"Biogen Press Release, Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer\u2019s Disease, http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials, Posted March 21, 2019, Accessed March 29, 2019."},{"key":"ref081","unstructured":"Biogen Press Release, Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months, http:\/\/investors.biogen.com\/news-releases\/news-release-details\/eisai-and-biogen-announce-positive-topline-results-final, Posted July 5, 2018, Accessed February 13, 2019."},{"key":"ref082","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0189-7"},{"key":"ref083","unstructured":"Release, Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer\u2019s disease (AD) - other company programmes in AD continue, https:\/\/www.roche.com\/media\/releases\/med-cor-2019-01-30.htm, Posted January 30, 2019, Accessed March 29, 2019."},{"key":"ref084","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"ref085","unstructured":"Lilly Press Release, Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, https:\/\/investor.lilly.com\/static-files\/9117f89a-0f6a-4dd8-a73e-97c108cf613d, Posted November 23, 2016, Accessed February 13, 2019."},{"key":"ref086","unstructured":"BioSpace, Eli Lilly Washes Its Hands of Another Phase 3 Study After the Failure of Solanezumab, https:\/\/www.biospace.com\/article\/eli-lilly-washes-its-hands-of-another-phase-3-study-after-the-failure-of-solanezumab-\/ Posted February 2, 2017, Accessed March 29, 2019."},{"issue":"7","key":"ref087","first-page":"P351","volume":"12","author":"Gauthier S","year":"2016","journal-title":"Alzheimers Dement"},{"key":"ref088","first-page":"1","volume":"8","author":"Zhang C","year":"2018","journal-title":"Sci Rep"},{"key":"ref089","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.586602"},{"key":"ref090","unstructured":"ElmalehDR. Combination Therapies for Treatment of Alzheimer\u2019s Disease and Related Disorders. US 9,855,276 B2, 2018."},{"key":"ref091","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12491"},{"key":"ref092","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06624-y"},{"key":"ref093","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15213"},{"key":"ref094","first-page":"82","volume":"2","author":"Aisen PS","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"ref095","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000344650.95823.03"},{"key":"ref096","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.01.005"},{"key":"ref097","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0177-y"},{"key":"ref098","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"ref099","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000364"},{"key":"ref100","unstructured":"Lilly Press Release, Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer\u2019s Disease, https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-voluntarily-terminates-phase-ii-study-ly2886721-beta, Posted June 13, 2016, Accessed February 13, 2019."},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0173-2"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)70016-5"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-017-0816-5"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.2217\/fnl-2017-0009"},{"key":"ref107","first-page":"748","volume":"140","author":"Pontecorvo MJ","year":"2017","journal-title":"Brain"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-190507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-190507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-190507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:41Z","timestamp":1777370801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-190507"}},"subtitle":[],"editor":[{"given":"Carmela","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,10,1]]}},"alternative-id":["10.3233\/JAD-190507"],"URL":"https:\/\/doi.org\/10.3233\/jad-190507","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]}}}